SR Pharma starts Phase II SRP299 trial

SR Pharma (LSE:SPA) started a placebo-controlled U.K. Phase II study of its SRP299 to treat moderate to severe atopic dermatitis (eczema) in 120 children ages 5-16. SRP299 is a heat-killed suspension ...